| abstract |
Implant assemblies (10) and methodologies provide immuno-protection for implanted allografts, xenografts, and isografts. The assemblies and methodologies establish an improved boundary (34) between the host and the implanted cells. The boundary (34) has a pore size, an ultimate strength, and a metabolic transit value that assures the survival of the cells during the critical ischemic period and afterward. The boundary (34) allows the fabrication and clinical use of implant assemblies (10) and methodologies that can carry enough cells to be of therapeutic value to the host, yet occupy a relatively small, compact area within the host. |